In updating its compliance programs, Wal-Mart (NYSE: WMT ) has finally applied the advice of investing genius Charlie Munger to "never, ever think about something else when you should be thinking about the power of incentives."
In its 2013 proxy, the Bentonville Behemoth announced that it would tie executive pay to compliance improvements. In doing so, it is giving leadership a strong incentive to strengthen the company's compliance systems in addition to improving its sales, operating income, and return on investment.
This is a progressive move. But if Wal-Mart wishes to take meaningful steps toward reducing compliance risks, I believe it needs to do more.
Strong compliance requires empowerment
Without empowerment, it doesn't matter how much employees want to meet key standards or how much they stand to gain by achieving them. If they can't meet a standard, they won't. This means that if Wal-Mart wants to meet its compliance goals, it needs to empower its compliance professionals to do their jobs well in addition to motivating executives to improve its compliance program.
Hot Long Term Stocks To Buy Right Now: Targacept Inc.(TRGT)
Targacept, Inc., a biopharmaceutical company, engages in the discovery, design, and development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of diseases and disorders of the nervous system. Its products include TC-5214, a nicotinic channel modulator, which is in Phase III clinical trials as an adjunct treatment for depressive disorder; and in Phase IIb clinical trial for switch monotherapy in patients with depressive disorder. The company?s small molecule products include TC-5619, which is under two separate Phase II clinical trials to treat negative symptoms and cognitive dysfunction in schizophrenia, inattentive-predominant attention deficit/hyperactivity disorder, and Alzheimer?s disease; AZD3480, a product under Phase IIb clinical trials for the treatment of mild to moderate Alzheimer?s disease; AZD1446 for treatment of Alzheimer?s disease; TC-6987 under Phase II clinical trials to treat asthma and type 2 diabetes; and TC-6499 for the treatm ent for gastrointestinal disorders. It has a collaborative research and license agreement with AstraZeneca AB for the development and commercialization of AZD3480, TC-5214, and TC-5619; and a product development and commercialization agreement with SmithKline Beecham Corporation and Glaxo Group Limited to discover, develop, and market product candidates that selectively target specified NNR subtypes in specified therapeutic focus areas. Targacept, Inc. was founded in 1997 and is based in Winston-Salem, North Carolina.
Advisors' Opinion:- [By Lauren Pollock]
Targacept Inc.'s(TRGT) investigational secondary treatment for schizophrenia didn’t show significant improvement in negative symptoms or cognitive function in a Phase 2b trial after 24 weeks. The biopharmaceutical company said it wouldn’t pursue further development of the therapy for the mental illness or for Alzheimer’s Disease. Shares fell 31% to $4.09 premarket.
- [By Anna Prior]
Targacept Inc.(TRGT) �said it will drop a clinical-stage treatment for Alzheimer’s disease after seeing disappointing results in a midstage study. Shares fell 4.8% to $4.20 premarket.
- [By DailyFinance Staff]
Investors took a wait-and-see attitude Tuesday, but airline stocks lost altitude. The market is in a holding pattern until 2 p.m. Wednesday, when the Fed reveals details of this week's FOMC policy meetings, and whether it's ready to begin cutting back on its main economic stimulus program. If it does begin to taper, the next debate will begin immediately: Is that good or bad for investors? On Wall Street today, the Dow Jones industrial average (^DJI) edged down 9 points, the Nasdaq composite (^IXIC) fell nearly 6, and the Standard & Poor's 500 index (^GPSC) lost 5 points. The Dow's gainers were led by a pair of companies hiking their dividends. 3M (MMM), which makes everything from Post-It notes to medical equipment, rose 3 percent after increasing its payout by 35 percent. And Boeing (BA) rose 1 percent. It boosted the dividend by 50 percent and announced a big stock buyback. The other big blue chip winner was Visa (V), which gained another 2.5 percent. Its stock is now up 43 percent from a year ago. On the downside, Verizon (VZ), IBM (IBM), McDonald's (MCD) and Microsoft (MSFT) all lost about one percent. Microsoft says it will not name a new CEO until next year. And airline stocks were broadly lower. United (UAL) and Delta (DAL) both fell 3 percent. American Airlines (AAL), which completed its merger with U.S. Airways last week, fell 2 percent. And Southwest (V) also lost 2 percent. Brokerage recommendations gave a boost to several issues. Data storage companies Seagate (STX), up 3 percent, and Western Digital (WDC), up 2.5 percent, following JP Morgan upgrades. And iRobot (IRBT) surged 17 percent after Raymond James gave it a 'strong buy.' Shares of Facebook (FB) rose 2 percent, hitting an all-time high. The social media giant is rolling out new video ads this week. That's expected to boost revenue. The question is, will it alienate users? On the downside, Targacept (TRGT) lost more than a third of its value. A clinical trial of its schizophreni
Best Diversified Bank Companies To Invest In Right Now: Vical Incorporated(VICL)
Vical Incorporated engages in the research and development of biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its products include Allovectin, a Phase III clinical trial product to treat metastatic melanoma; CyMVectin prophylactic vaccine for cytomegalovirus, which completed preclinical trial to prevent infection before pregnancy to preclude fetal transmission; and therapeutic and prophylactic vaccines for herpes simplex type 2 virus, which is under preclinical trial to prevent and protect against recurring flare-ups, reduce viral shedding ,and transmission. The company, through corporate collaborations, develops TransVax, which is in Phase III clinical trials to protect against CMV infection after stem cell transplants, as well as in Phase II clinical trial to protect against CMV infection after solid organ transplants; Collategene, an angiogenic therapy enc oding hepatocyte growth factor that is in Phase III clinical trials to induce local growth of blood vessels to restore blood flow to limbs affected by critical limb ischemia; Apex-IHN prophylactic vaccine for infectious hematopoietic necrosis virus for the prevention of infection and disease in farm-raised salmon when exposed to infected wild salmon ; and ONCEPT therapeutic cancer vaccine encoding human tyrosinase for the treatment to increase survival time of dogs with oral melanoma. Vical Incorporated, through government collaboration, develops Prophylactic and/or therapeutic HIV vaccine, a Phase IIb clinical trial product to prevent/treat infection, disease, and/or viral shedding; and Tetravalent dengue vaccine, a Phase I clinical trial product to prevent dengue disease caused by all 4 dengue serotypes. The company was founded in 1987 and is based in San Diego, California.
Advisors' Opinion:- [By Rich Bieglmeier]
[Related -Vical (VICL) Licenses Vaxfectin Adjuvant For Use In Malaria Vaccines To Cyvax]
Vical researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases.
- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Vical (NASDAQ: VICL ) has received a distressing two-star ranking.
- [By Roberto Pedone]
Another stock that's starting to trend within range of triggering a major breakout trade is Vical (VICL), which engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. This stock has been hit hard by the sellers over the last six months, with shares off sharply by 65%.
If you look at the chart for Vical, you'll notice that this stock has been trending sideways and consolidating over the last two months, with shares moving between $1.01 on the downside and $1.35 on the upside. Shares of VICL have started to uptrend over the last few weeks, with shares moving higher from its low of $1.01 to its recent high of $1.35 a share. During that move, shares of VICL have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now taken shares of VICL back above its 50-day moving average of $1.16 share and it's quickly pushing the stock within range of triggering a major breakout trade.
Traders should now look for long-biased trades in VICL if it manages to break out above some near-term overhead resistance at $1.35 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.17 million shares. If that breakout hits soon, then VICL will set up to re-test or possibly take out its next major overhead resistance level at $1.53 a share to its gap-down day high of $1.61 a share. Any high-volume move above those levels will then give VICL a chance to re-fill some of its previous gap-down-day zone from last August that started at $3.70 a share.
Traders can look to buy VICL off any weakness to anticipate that breakout and simply use a stop that sits just below its 50-day moving average at $1.20 a share or near more support at $1.10 a share. One can also buy VICL off strength once it starts to cle
- [By Roberto Pedone]
Vical (VICL) engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. This stock closed up 5.8% to $1.62 in Tuesday's trading session.
Tuesday's Range: $1.53-$1.63
52-Week Range: $1.37-$4.74
Tuesday's Volume: 7.28 million
Three-Month Average Volume: 1.53 millionFrom a technical perspective, VICL bounced higher here right above its recent 52-week low at $1.37 with monster upside volume. This stock recently gapped down big from $3.75 to $1.37 with huge downside volume. That move has now pushed shares of VICL into extremely oversold territory, since its current relative strength index reading is 21.80. Oversold can always get more oversold, but it's also an area where a stock can experience a powerful bounce higher from.
Traders should now look for long-biased trades in VICL as long as it's trending above its 52-week low at $1.37 and then once it sustains a move or close above Tuesday's high of $1.63 with volume that hits near or above 1.53 million shares. If we get that move soon, then VICL will set up to re-fill some of its previous gap down zone that started at $3.75. Some possible upside targets if VICL gets into that gap with volume are $2.25 to $2.50.
Best Diversified Bank Companies To Invest In Right Now: Auxilium Pharmaceuticals Inc.(AUXL)
Auxilium Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company primarily in the United States. It focuses on developing and marketing products to urologists, endocrinologists, primary care physicians, hand surgeons, and rheumatologists, as well as to orthopedic, general, and plastic surgeons. The company markets XIAFLEX (collagenase clostridium histolyticum), an injectable collagenase enzyme for the treatment of adult Dupuytren?s contracture; and Testim, a topical 1% testosterone gel for the treatment of hypogonadism. The company?s clinical development products include XIAFLEX that is in Phase III clinical trials for the treatment of Peyronie?s disease, as well as in Phase II clinical trials for the treatment of Adhesive Capsulitis. In addition, it has rights to develop other products for the treatment of pain, urologic disease, and hormone replacement using its transmucosal film delivery system. The company has a strategic alliance with Asahi Kasei Ph arma Corporation for the development, commercialization, and supply of XIAFLEX, a biologic for the treatment of Dupuytren?s contracture and Peyronie?s disease. Auxilium Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Malvern, Pennsylvania.
Advisors' Opinion:- [By Sean Williams]
Also, the testosterone market is also glutted with competition and Aveed, even will likely have a hard time making any meaningful impact for Endo. AbbVie (NYSE: ABBV ) recently reformulated its AndroGel testosterone treatment into a more potent form at 1.62% and in 2011 received FDA approval after 82% of hypogonadal men achieved normal testosterone levels after 112 days. Also operating in the gel space is Auxilium Pharmaceuticals' (NASDAQ: AUXL ) drug Testim, which achieved $45.5 million in sales in the first quarter. That figure actually represents a 23% year-over-year decline because of difficulties in gaining insurance coverage for the gel, but it's yet another hurdle for Aveed to jump over if it were to reach market.
- [By Roberto Pedone]
One potential earnings short-squeeze candidate is biotechnology player Auxilium Pharmaceuticals (AUXL), which is set to release numbers on Thursday before the market open. Wall Street analysts, on average, expect Auxilium Pharmaceuticals to report revenue of $91.43 million on a loss of 3 cents per share.
During the last quarter, this company reported revenue of $66.2 million and GAAP reported sales were 10% lower than the prior-year quarter's $73.6 million. Also during the last quarter, this company reported non-GAAP EPS of -12 cents per share and GAAP EPS of -17 cents per share.
The current short interest as a percentage of the float for Auxilium Pharmaceuticals is pretty high at 11.1%. That means that out of the 39.84 million shares in the tradable float, 5.14 million shares are sold short by the bears. This is a decent short interest on a stock with a relatively low tradable float. If the bulls get the earnings news they're looking for, then shares of AUXL could easily rip higher post-earnings as the bears rush to cover some of their short bets.
From a technical perspective, AUXL is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last three months, with shares soaring higher from its low of $13.87 to its intraday high of $18.42 a share. During that uptrend, shares of AUXL have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of AUXL within range of triggering a major breakout trade post-earnings.
If you're bullish on AUXL, then I would wait until after its report and look for long-biased trades if this stock manages to break out above some key overhead resistance levels at $18.50 to $19.60 a share with high volume. Look for volume on that move that registers near or above its three-month average action of 834,059 shares. If that breakout hits, then AUXL will set up
- [By Jake L'Ecuyer]
Auxilium Pharmaceuticals (NASDAQ: AUXL) was also up, gaining 12.11 percent to $21.67 following FDA approval of its Peyronie's disease treatment, Xiaflex.
Best Diversified Bank Companies To Invest In Right Now: Verifone Systems Inc.(PAY)
Verifone Systems, Inc. designs, markets, and services electronic payment solutions in North America and internationally. It provides system solutions, including countertop electronic payment systems that accepts magnetic, smart card, contactless/ radio frequency identification(RFID) cards, and near field communication(NFC) enabled mobile phones; secure PIN pads that support credit and debit transactions; and wireless system solutions that support Internet protocol-based code division multiple access, general packet radio service, bluetooth, and wireless fidelity technologies. The company also offers products for consumer-activated functionality at the point of sale; contactless/NFC payment solutions consisting of contactless readers primarily for consumer-activated transactions with contactless cards, tokens, and NFC-enabled mobile phones; and Gemstone family of products comprising integrated electronic payment systems for petroleum companies. In addition, it provides serv er-based payment processing software and middleware; unattended and self-service payments hardware and software integration modules, such as vending machines, ATMs, ticketing kiosks, petroleum dispensers, public transportation turnstiles and buses, self-checkout, bill payment, and photo finishing kiosks; retail bank branch solutions; mass transportation solutions; and network access solutions. Further, the company offers client services, customized application development, advertising publishing, taxi payments and advertising, cardholder data security, annual software maintenance program, and repair services. It serves financial institutions, payment processors, petroleum companies, large retailers, taxi fleets, government organizations, healthcare companies, independent sales organizations, and advertisers. The company was formerly known as VeriFone Holdings, Inc. and changed its name to VeriFone Systems, Inc in May 2010. VeriFone Systems, Inc. is headquartered in San Jose, California.
Advisors' Opinion:- [By Monica Gerson]
VeriFone Systems (NYSE: PAY) is expected to report its Q3 earnings at $0.35 per share on revenue of $458.93 million.
Joy Global (NYSE: JOY) is estimated to report its Q3 earnings at $0.84 per share on revenue of $934.25 million.
- [By Roland Head]
VeriFone (NYSE: PAY ) may fall this morning after the firm revealed a second-quarter loss of $0.54 per share after markets closed last night, down from a $0.03 per-share profit for the same period last year. The firm blamed high legal costs for the loss, but its shares closed down by 5% last night and are down by almost 15% in premarket trading this morning. Vera Bradley may also fall after reporting a 27% fall in first-quarter profit and cutting its full-year guidance; the handbag designer's share price is down 11% in premarket trading this morning.
Best Diversified Bank Companies To Invest In Right Now: Titan Machinery Inc (TITN)
Titan Machinery Inc., incorporated in 1980, owns and operates a network of agricultural and construction equipment stores in the United States and Europe. The Company is a retail dealer of Case IH Agriculture equipment and a retail dealer of New Holland Agriculture, Case Construction and New Holland Construction equipment in the United States. It operates in two segments: Agriculture and Construction. The agricultural equipment, which it sells and services includes machinery and attachments for uses ranging from large-scale farming to home and garden use. The construction equipment it sells and services includes heavy construction and light industrial machinery for commercial and residential construction, road and highway construction and mining. On February 28, 2011, it acquired certain assets of Tri-State Implement, Inc. On March 31, 2011, the Company acquired interest in Schoffman's Inc. In July 2012, the Company acquired Curly Olney��, Inc. and opened two Case IH dealerships in Cluj and Roman, Romania. In November 2012, the Company acquired Falcon Power Inc. In December 2012, the Company acquired VAIT D.o.o. In February 2013, it acquired Tucson Tractor Company. In March 2013, it acquired Adobe CE, LLC, consisting of one Case Construction equipment dealership located in Albuquerque, New Mexico.
On April 1, 2011, the Company acquired certain assets of ABC Rental & Equipment Sales. On May 13, 2011, the Company acquired certain assets of Carlson Tractor & Equipment, Inc. On May 31, 2011, the Company acquired certain assets of St. Joseph Equipment Inc. On September 2, 2011, the Company acquired certain assets of Virgl Implement Inc. On September 2, 2011, the Company acquired certain assets of Victors Inc. On November 1, 2011, the Company acquired certain assets of Van Der Werff Implement, Inc. On December 1, 2011, the Company acquired certain assets of Jewell Implement Company, Inc. On December 23, 2011, the Company, through a newly formed subsidiary, Titan Machinery Romania, S.R.L., ac! quired certain assets of AgroExpert Capital S.R.L. On February 27, 2012, the Company acquired certain assets of the Colorado division of Adobe Truck & Equipment, LLC. On March 5, 2012, the Company acquired certain assets of Rimex 1-Holding EAD. On March 30, 2012, the Company acquired certain assets of Haberer's Implement, Inc. On April 2, 2012, the Company acquired certain assets of East Helena Rental, LLC.
Equipment Sales
The Company sells agricultural and construction equipment manufactured under the CNH family of brands, as well as equipment from a variety of other manufacturers. The used equipment it sells is from inventory acquired through trade-ins from its customers and selective purchases. The agricultural equipment, which it sells and services includes application equipment and sprayers, combines and attachments, hay and forage equipment, planting and seeding equipment, precision farming technology, tillage equipment and tractors. The construction equipment, which the Company sells and services includes articulated trucks, compact track loaders, compaction equipment, cranes, crawler dozers, excavators, forklifts, loader/backhoes, loader/tool carriers, motor graders, skid steer loaders, telehandlers and wheel loaders. The Company also sells used equipment through its outlet stores.
Parts Sales
The Company sells a range of maintenance and replacement parts on equipment that it sells, as well as other types of equipment. It maintains an in-house parts inventory to provide parts, and repair and maintenance support to its customers.
Repair and Maintenance Services
The Company provides repair and maintenance services, including warranty repairs, for its customers equipment. In addition, the Company provides customer service by maintaining service histories for each piece of equipment owned by its customers, maintaining around-the-clock service hours, providing on-site repair services, scheduling off-season maintenance acti! vities wi! th customers, notifying customers of periodic service requirements and providing training programs to customers.
Equipment Rental and Other Business Activities
The Company rents equipment to its customers on a short-term basis for periods ranging from a few days to a few months. In addition, the Company provides ancillary equipment support activities, such as equipment transportation, global positioning system (GPS) signal subscriptions in connection with precision farming and reselling CNH Capital finance and insurance products.
The Company competes with RDO Equipment Co., Butler Machinery, Ziegler Inc. and Brandt Holdings Co.
Advisors' Opinion:- [By Seth Jayson]
Titan Machinery (Nasdaq: TITN ) reported earnings on June 6. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended April 30 (Q1), Titan Machinery met expectations on revenues and met expectations on earnings per share.
Best Diversified Bank Companies To Invest In Right Now: Vanguard FTSE All World ex US Index Fund Investor Shares (VEU)
Vanguard FTSE All-World ex-US ETF (the Fund) is an exchange-traded class of shares of Vanguard FTSE All-World ex-US Index Fund. The Fund seeks to track the performance of an index that measures the investment return of stocks of companies located in developed and emerging markets worldwide. The Fund employs a passive management or indexing investment approach designed to track the performance of the FTSE All-World ex US Index (the Index), a free-float-adjusted, market capitalization-weighted index designed to measure equity market performance of international markets.
The Index includes approximately 2,200 stocks of companies located in 47 countries, including both developed and emerging markets. The Fund typically holds 1,200 to 1,300 stocks in the Index (covering nearly 95% of the Index�� total market capitalization) and a representative sample of the remaining stocks. The Fund holds a range of securities that, in the aggregate, approximate the full Index in terms of key characteristics. These key characteristics include industry weightings and market capitalization, as well as certain financial measures, such as price/earnings ratio and dividend yield. The Fund�� investment advisor is The Vanguard Group, Inc.
Advisors' Opinion:- [By Philip Springer, President, Retirement Wealth Management, Inc.]
Our favorite is Vanguard FTSE All-World ex-US (VEU). This all-in-one ETF combines broad diversification, a high yield (4.7%) and a rock-bottom expense ratio (0.15%).
No comments:
Post a Comment